|
DGAP-News: PAION AG
/ Key word(s): Market launch
PAION ANNOUNCES PRODUCT LAUNCH OF BYFAVOTM (REMIMAZOLAM) IN SOUTH KOREA BY HANA PHARM Aachen (Germany), 07 April 2021 - The Specialty Pharma Company PAION AG (PA8; ISIN DE000A0B65S3; Frankfurt Stock Exchange Prime Standard) today announces that Hana Pharm, remimazolam licensee for South Korea, informed PAION about the launch of ByfavoTM (remimazolam) for the use in general anesthesia in South Korea. Remimazolam was approved in South Korea for general anesthesia in January 2021 and will be marketed under the brand name ByfavoTM. Dr. Jim Phillips, Chief Executive Officer of PAION AG, stated: "The launch in South Korea is great news and a testament to the strong commitment of our partner Hana Pharm. PAION is eligible to royalties of 10% of net sales in South Korea. We look forward to a successful 4th country launch and sharing further commercial news when we receive it regarding the South Korean market." ### About remimazolam Remimazolam is approved in the U.S., the EU/EEA and China for procedural sedation and in Japan and South Korea for general anesthesia. In addition to procedural sedation and general anesthesia, intensive care unit (ICU) sedation is another possible indication for remimazolam. Remimazolam is partnered in the U.S. (brand name BYFAVOTM) with Acacia Pharma, in Japan (brand name Anerem(R)) with Mundipharma, in China (brand name Ruima(R)) with Yichang Humanwell, in Canada with Pharmascience, in Russia/CIS, Turkey and the MENA region with R-Pharm, in South Korea (brand name ByfavoTM) and Southeast Asia with Hana Pharm and in Taiwan with TTY Biopharm. For all other markets except Western Europe, remimazolam is available for licensing. About PAION In addition to Byfavo(R) (remimazolam), PAION is preparing to launch the two products GIAPREZA(R) (Angiotensin II) and XERAVA(R) (Eravacycline) in Europe. GIAPREZA(R) is a vasoconstrictor indicated for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies. XERAVA(R) is a novel fluorocycline indicated for the treatment of complicated intra-abdominal infections in adults. PAION's mission is to be a leading specialty pharmaceutical company in the fields of anesthesia and critical care by bringing novel products to market to benefit patients, doctors and other stakeholders in healthcare. PAION is headquartered in Aachen (Germany). Contact
07.04.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. |
| Language: | English |
| Company: | PAION AG |
| Heussstraße 25 | |
| 52078 Aachen | |
| Germany | |
| Phone: | +49 (0)241-4453-0 |
| Fax: | +49 (0)241-4453-100 |
| E-mail: | |
| Internet: | |
| ISIN: | DE000A0B65S3 |
| WKN: | A0B65S |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 1181362 |
| End of News | DGAP News Service |
|
|
1181362 07.04.2021
